Eli Lilly and Co. has signed a definitive merger agreement to acquire Avid Radiopharmaceuticals, Inc., a developer of novel molecular imaging compounds, for an upfront payment of $300 million. Avid’s lead program, florbetapir F 18 (18F-AV-45), is a molecular imaging agent in development for detecting the presence of amyloid plaque in the brain, a defining pathology of Alzheimer’s disease. A marketing application for florbetapir was recently submitted to FDA. Avid stockholders will al...